Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $23.46, but opened at $21.64. Exelixis shares last traded at $21.17, with a volume of 911,024 shares trading hands. The biotechnology company reported $0.12 […]
Exelixis (NASDAQ:EXEL – Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16), Briefing.com reports. The company had revenue of $425.23 million during the quarter, compared to analysts’ expectations of $461.04 million. Exelixis had a return on equity […]
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 8,620,000 shares, an increase of 26.2% from the March 31st total of 6,830,000 shares. Approximately 3.0% of the company’s shares are sold short. Based on an average […]
Meritage Portfolio Management raised its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 7.0% in the 4th quarter, Holdings Channel reports. The fund owned 422,676 shares of the biotechnology company’s stock after acquiring an additional 27,815 shares during the period. Meritage Portfolio Management’s holdings in Exelixis were worth $10,140,000 as of its most recent […]